NCT03029455View on ClinicalTrials.gov

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

PHASE1CompletedINTERVENTIONAL

Enrollment

163

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-659

DRUG

Tezacaftor

DRUG

Ivacaftor

DRUG

VX-659 Matching Placebo

DRUG

Triple Combination (TC) Matching Placebos

Trial Locations (10)

Unknown

Birmingham

Cambridge

Exeter

Glasgow

Leeds

Liverpool

London

Manchester

Newcastle upon Tyne

Southampton

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT03029455 - A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis | Biotech Hunter | Biotech Hunter